A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-05-19

AUTHORS

Khaldoun Almhanna, David Wright, Teresa Macarulla Mercade, Jean-Luc Van Laethem, Antonio Cubillo Gracian, Carmen Guillen-Ponce, Jason Faris, Carolina Muriel Lopez, Richard A. Hubner, Johanna Bendell, Alain Bols, Jaime Feliu, Naureen Starling, Peter Enzinger, Devalingham Mahalingham, Wells Messersmith, Huyuan Yang, Adedigbo Fasanmade, Hadi Danaee, Thea Kalebic

ABSTRACT

Background This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC). Methods Patients with advanced or metastatic pancreatic adenocarcinoma expressing GCC (H-score ≥ 10) received TAK-264 1.8 mg/kg on day 1 of a 21-day cycle as a 30-min intravenous infusion for up to 1 year or until disease progression or unacceptable toxicity. The primary objective was overall response rate (ORR [complete response + partial response (PR)]). Secondary objectives included evaluations of the safety and pharmacokinetic profile of TAK-264 (NCT02202785). Results 43 patients were enrolled and treated with 1.8 mg/kg TAK-264: 11, 15, and 17 patients with low, intermediate, and high GCC expression, respectively. Median number of treatment cycles received was two (range 1–10). The ORR was 3%, including one patient with intermediate GCC expression who achieved a PR. All patients experienced ≥1 adverse events (AE). The majority of patients experienced grade 1/2 AEs affecting the gastrointestinal tract. Fifteen (35%) patients experienced ≥grade 3 drug-related AEs; five (12%) patients had a serious AE. The most common (≥10% of patients) all-grade drug-related AEs were nausea (33%), fatigue (28%), neutropenia (23%), decreased appetite (23%), vomiting (16%), asthenia (16%), and alopecia (14%). Conclusions TAK-264 demonstrated a manageable safety profile; however, the low efficacy of TAK-264 observed in this study did not support further clinical investigation. More... »

PAGES

634-641

Journal

TITLE

Investigational New Drugs

ISSUE

5

VOLUME

35

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-017-0473-9

DOI

http://dx.doi.org/10.1007/s10637-017-0473-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085442130

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28527133


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Enterotoxin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, 33612, Tampa, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, 33612, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Almhanna", 
        "givenName": "Khaldoun", 
        "id": "sg:person.01027130140.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027130140.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Florida Cancer Specialists, Tampa, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.428633.8", 
          "name": [
            "Florida Cancer Specialists, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wright", 
        "givenName": "David", 
        "id": "sg:person.016267211647.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267211647.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vall d\u2019Hebron University Hospital, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Vall d\u2019Hebron University Hospital, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mercade", 
        "givenName": "Teresa Macarulla", 
        "id": "sg:person.015007444517.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007444517.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasme University Hospital, Brussels, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.412157.4", 
          "name": [
            "Erasme University Hospital, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Laethem", 
        "givenName": "Jean-Luc", 
        "id": "sg:person.013532355330.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013532355330.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departamento de Ciencias M\u00e9dicas Cl\u00ednicas, Universidad San Pablo CEU, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.8461.b", 
          "name": [
            "HM Universitario Sanchinarro, Centro Integral Oncol\u00f3gico Clara Campal (CIOCC), Madrid, Spain", 
            "Departamento de Ciencias M\u00e9dicas Cl\u00ednicas, Universidad San Pablo CEU, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gracian", 
        "givenName": "Antonio Cubillo", 
        "id": "sg:person.07564140447.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07564140447.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ram\u00f3n y Cajal University Hospital, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411347.4", 
          "name": [
            "Ram\u00f3n y Cajal University Hospital, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guillen-Ponce", 
        "givenName": "Carmen", 
        "id": "sg:person.01073066024.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073066024.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Massachusetts General Hospital Cancer Center, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Massachusetts General Hospital Cancer Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faris", 
        "givenName": "Jason", 
        "id": "sg:person.0634644023.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634644023.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411062.0", 
          "name": [
            "Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lopez", 
        "givenName": "Carolina Muriel", 
        "id": "sg:person.011754462047.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011754462047.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Christie NHS Foundation Trust, Manchester, UK", 
          "id": "http://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "The Christie NHS Foundation Trust, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hubner", 
        "givenName": "Richard A.", 
        "id": "sg:person.01126575447.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126575447.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.419513.b", 
          "name": [
            "Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bendell", 
        "givenName": "Johanna", 
        "id": "sg:person.01174064377.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174064377.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brugge Oostende Oncologisch Centrum, Bruges, Belgium", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Brugge Oostende Oncologisch Centrum, Bruges, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bols", 
        "givenName": "Alain", 
        "id": "sg:person.01270750543.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270750543.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CIBERONC, La Paz University Hospital, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.81821.32", 
          "name": [
            "CIBERONC, La Paz University Hospital, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feliu", 
        "givenName": "Jaime", 
        "id": "sg:person.01272603724.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272603724.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Royal Marsden NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "Naureen", 
        "id": "sg:person.01136565472.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana Farber Cancer Institute, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana Farber Cancer Institute, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Enzinger", 
        "givenName": "Peter", 
        "id": "sg:person.01162124377.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162124377.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Texas Health Science Center, San Antonio, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.267309.9", 
          "name": [
            "University of Texas Health Science Center, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahalingham", 
        "givenName": "Devalingham", 
        "id": "sg:person.016450520717.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016450520717.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "University of Colorado, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Messersmith", 
        "givenName": "Wells", 
        "id": "sg:person.01221726245.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221726245.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419849.9", 
          "name": [
            "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Huyuan", 
        "id": "sg:person.01365645263.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365645263.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419849.9", 
          "name": [
            "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fasanmade", 
        "givenName": "Adedigbo", 
        "id": "sg:person.01050203042.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050203042.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419849.9", 
          "name": [
            "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Danaee", 
        "givenName": "Hadi", 
        "id": "sg:person.01053064323.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053064323.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419849.9", 
          "name": [
            "Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalebic", 
        "givenName": "Thea", 
        "id": "sg:person.013033516104.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013033516104.84"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13277-011-0231-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022738216", 
          "https://doi.org/10.1007/s13277-011-0231-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13238-016-0323-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034018913", 
          "https://doi.org/10.1007/s13238-016-0323-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1014231722696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012970787", 
          "https://doi.org/10.1023/a:1014231722696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.435", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005211799", 
          "https://doi.org/10.1038/bjc.2015.435"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-05-19", 
    "datePublishedReg": "2017-05-19", 
    "description": "Background This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC). Methods Patients with advanced or metastatic pancreatic adenocarcinoma expressing GCC (H-score\u00a0\u2265\u00a010) received TAK-264 1.8\u00a0mg/kg on day 1 of a 21-day cycle as a 30-min intravenous infusion for up to 1\u00a0year or until disease progression or unacceptable toxicity. The primary objective was overall response rate (ORR [complete response + partial response (PR)]). Secondary objectives included evaluations of the safety and pharmacokinetic profile of TAK-264 (NCT02202785). Results 43 patients were enrolled and treated with 1.8\u00a0mg/kg TAK-264: 11, 15, and 17 patients with low, intermediate, and high GCC expression, respectively. Median number of treatment cycles received was two (range 1\u201310). The ORR was 3%, including one patient with intermediate GCC expression who achieved a PR. All patients experienced \u22651 adverse events (AE). The majority of patients experienced grade 1/2 AEs affecting the gastrointestinal tract. Fifteen (35%) patients experienced \u2265grade 3 drug-related AEs; five (12%) patients had a serious AE. The most common (\u226510% of patients) all-grade drug-related AEs were nausea (33%), fatigue (28%), neutropenia (23%), decreased appetite (23%), vomiting (16%), asthenia (16%), and alopecia (14%). Conclusions TAK-264 demonstrated a manageable safety profile; however, the low efficacy of TAK-264 observed in this study did not support further clinical investigation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-017-0473-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "metastatic pancreatic adenocarcinoma", 
      "drug-related adverse events", 
      "TAK-264", 
      "adverse events", 
      "guanylyl cyclase C", 
      "pancreatic adenocarcinoma", 
      "GCC expression", 
      "grade 1/2 adverse events", 
      "serious adverse events", 
      "manageable safety profile", 
      "phase II study", 
      "cyclase C", 
      "majority of patients", 
      "overall response rate", 
      "further clinical investigation", 
      "antibody-drug conjugates", 
      "Methods Patients", 
      "unacceptable toxicity", 
      "II study", 
      "multicenter study", 
      "safety profile", 
      "intravenous infusion", 
      "disease progression", 
      "median number", 
      "gastrointestinal tract", 
      "clinical investigation", 
      "patients", 
      "pharmacokinetic profile", 
      "day 1", 
      "response rate", 
      "treatment cycles", 
      "secondary objective", 
      "adenocarcinoma", 
      "low efficacy", 
      "phase II", 
      "efficacy", 
      "primary objective", 
      "safety", 
      "tolerability", 
      "neutropenia", 
      "vomiting", 
      "asthenia", 
      "alopecia", 
      "infusion", 
      "expression", 
      "tract", 
      "progression", 
      "appetite", 
      "study", 
      "toxicity", 
      "profile", 
      "majority", 
      "fatigue", 
      "objective", 
      "years", 
      "conjugates", 
      "evaluation", 
      "background", 
      "rate", 
      "events", 
      "cycle", 
      "PR", 
      "number", 
      "investigation", 
      "ORR"
    ], 
    "name": "A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C", 
    "pagination": "634-641", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085442130"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-017-0473-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28527133"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-017-0473-9", 
      "https://app.dimensions.ai/details/publication/pub.1085442130"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_723.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-017-0473-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0473-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0473-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0473-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0473-9'


 

This table displays all metadata directly associated to this object as RDF triples.

380 TRIPLES      21 PREDICATES      108 URIs      96 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-017-0473-9 schema:about N07005aaef7ed4d9083f6eb8fa4784f68
2 N2a29f4ae2dc04dd585f743a5548090fb
3 N2dda251e8b804cbaa12be1bf1c2d59ef
4 N38bdedc587d547d6820f99a3703dadca
5 N4eee046ec8cd4db4b593288d291962d5
6 N5cde45cc79bf4cc39ad667106caf8cfb
7 N62babadd6b9d4e21947e41e51d9b718f
8 N8cb7fda3e61b42149cf4aa7c47e84caa
9 N9f3057379fd04f12beb1b9757f133c89
10 Nabd2eef6980e4bfbbec08ddac298ade6
11 Nd133d4f886fd47a8afc33d02b7a99776
12 Ne7849ceb94494fd0825348e13d0d6103
13 Nf42aca013f994da690d8de72050f927e
14 Nfb1fc93be0264f9dbc428faff9cfdc17
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N3ab5e1a458cb4ba497cc85de6afba31d
18 schema:citation sg:pub.10.1007/s13238-016-0323-0
19 sg:pub.10.1007/s13277-011-0231-0
20 sg:pub.10.1023/a:1014231722696
21 sg:pub.10.1038/bjc.2015.435
22 schema:datePublished 2017-05-19
23 schema:datePublishedReg 2017-05-19
24 schema:description Background This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC). Methods Patients with advanced or metastatic pancreatic adenocarcinoma expressing GCC (H-score ≥ 10) received TAK-264 1.8 mg/kg on day 1 of a 21-day cycle as a 30-min intravenous infusion for up to 1 year or until disease progression or unacceptable toxicity. The primary objective was overall response rate (ORR [complete response + partial response (PR)]). Secondary objectives included evaluations of the safety and pharmacokinetic profile of TAK-264 (NCT02202785). Results 43 patients were enrolled and treated with 1.8 mg/kg TAK-264: 11, 15, and 17 patients with low, intermediate, and high GCC expression, respectively. Median number of treatment cycles received was two (range 1–10). The ORR was 3%, including one patient with intermediate GCC expression who achieved a PR. All patients experienced ≥1 adverse events (AE). The majority of patients experienced grade 1/2 AEs affecting the gastrointestinal tract. Fifteen (35%) patients experienced ≥grade 3 drug-related AEs; five (12%) patients had a serious AE. The most common (≥10% of patients) all-grade drug-related AEs were nausea (33%), fatigue (28%), neutropenia (23%), decreased appetite (23%), vomiting (16%), asthenia (16%), and alopecia (14%). Conclusions TAK-264 demonstrated a manageable safety profile; however, the low efficacy of TAK-264 observed in this study did not support further clinical investigation.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf Nea1ae026034e44d6baae0f469c4384c5
28 Nfc8a78e8ff384899b707e9f18ea6fc25
29 sg:journal.1094201
30 schema:keywords GCC expression
31 II study
32 Methods Patients
33 ORR
34 PR
35 TAK-264
36 adenocarcinoma
37 adverse events
38 alopecia
39 antibody-drug conjugates
40 appetite
41 asthenia
42 background
43 clinical investigation
44 conjugates
45 cyclase C
46 cycle
47 day 1
48 disease progression
49 drug-related adverse events
50 efficacy
51 evaluation
52 events
53 expression
54 fatigue
55 further clinical investigation
56 gastrointestinal tract
57 grade 1/2 adverse events
58 guanylyl cyclase C
59 infusion
60 intravenous infusion
61 investigation
62 low efficacy
63 majority
64 majority of patients
65 manageable safety profile
66 median number
67 metastatic pancreatic adenocarcinoma
68 multicenter study
69 neutropenia
70 number
71 objective
72 overall response rate
73 pancreatic adenocarcinoma
74 patients
75 pharmacokinetic profile
76 phase II
77 phase II study
78 primary objective
79 profile
80 progression
81 rate
82 response rate
83 safety
84 safety profile
85 secondary objective
86 serious adverse events
87 study
88 tolerability
89 toxicity
90 tract
91 treatment cycles
92 unacceptable toxicity
93 vomiting
94 years
95 schema:name A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
96 schema:pagination 634-641
97 schema:productId N5e7301eff1154e8496082d96e361c2ef
98 N76b2acdd84a6442ab760bb2dc0acff0e
99 Nfad33f36e05d4f12a1fee1fd03c51611
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085442130
101 https://doi.org/10.1007/s10637-017-0473-9
102 schema:sdDatePublished 2022-10-01T06:42
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N3748ec1b22884a77a7a4b507cce66e81
105 schema:url https://doi.org/10.1007/s10637-017-0473-9
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N00f74a988ff048f0b1c79b3b9689e78e rdf:first sg:person.0634644023.27
110 rdf:rest Nd68c16360e7e4a929ce3d378f5001803
111 N07005aaef7ed4d9083f6eb8fa4784f68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 N08e5cc8e020c4503b51c6a0e3aa75dca rdf:first sg:person.01365645263.42
115 rdf:rest Ne652aa385e6f4e36aa2e3464a762296c
116 N2a29f4ae2dc04dd585f743a5548090fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Adenocarcinoma
118 rdf:type schema:DefinedTerm
119 N2dda251e8b804cbaa12be1bf1c2d59ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N3748ec1b22884a77a7a4b507cce66e81 schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 N38bdedc587d547d6820f99a3703dadca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Antibodies, Monoclonal, Humanized
126 rdf:type schema:DefinedTerm
127 N3ab5e1a458cb4ba497cc85de6afba31d rdf:first sg:person.01027130140.73
128 rdf:rest N8f8c06b9bd964f789104d7fda2bd5c3a
129 N44f19257bdb94b81b35750aef0bea2b5 rdf:first sg:person.016450520717.15
130 rdf:rest Ne22174745ec64eeb84684ba49d58a33d
131 N480e69c445584d099763e8a14c6f037d rdf:first sg:person.01162124377.34
132 rdf:rest N44f19257bdb94b81b35750aef0bea2b5
133 N4eee046ec8cd4db4b593288d291962d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Receptors, Enterotoxin
135 rdf:type schema:DefinedTerm
136 N5899a66ee0ae49ac9f83797fe580825c rdf:first sg:person.01174064377.38
137 rdf:rest Nfe3f39e2e5bc4e19b7e5af7d49eafc53
138 N5cde45cc79bf4cc39ad667106caf8cfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 N5e7301eff1154e8496082d96e361c2ef schema:name dimensions_id
142 schema:value pub.1085442130
143 rdf:type schema:PropertyValue
144 N62babadd6b9d4e21947e41e51d9b718f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aged
146 rdf:type schema:DefinedTerm
147 N6cc5e3cd10c047229e162a363c24a735 rdf:first sg:person.015007444517.20
148 rdf:rest Nb5980de2ee5d46bb95c411629c3a5fcb
149 N76b2acdd84a6442ab760bb2dc0acff0e schema:name doi
150 schema:value 10.1007/s10637-017-0473-9
151 rdf:type schema:PropertyValue
152 N81cebabd8a4248e5a15c401365dd03cb rdf:first sg:person.013033516104.84
153 rdf:rest rdf:nil
154 N8cb7fda3e61b42149cf4aa7c47e84caa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Antibodies, Monoclonal
156 rdf:type schema:DefinedTerm
157 N8eb34b91deab44e580c2867ee93d9db2 rdf:first sg:person.01126575447.10
158 rdf:rest N5899a66ee0ae49ac9f83797fe580825c
159 N8f8c06b9bd964f789104d7fda2bd5c3a rdf:first sg:person.016267211647.49
160 rdf:rest N6cc5e3cd10c047229e162a363c24a735
161 N9d265bbb602945a6b61fa3c2c8ed5659 rdf:first sg:person.01053064323.39
162 rdf:rest N81cebabd8a4248e5a15c401365dd03cb
163 N9f3057379fd04f12beb1b9757f133c89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Pancreatic Neoplasms
165 rdf:type schema:DefinedTerm
166 Nabd2eef6980e4bfbbec08ddac298ade6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Adult
168 rdf:type schema:DefinedTerm
169 Nb5980de2ee5d46bb95c411629c3a5fcb rdf:first sg:person.013532355330.01
170 rdf:rest Nf17f3c1c4244450983e757c39ff30391
171 Nbbb039aae64043058496f717ca9800cb rdf:first sg:person.01272603724.38
172 rdf:rest Nceeeb2c572a84b56bc29644caec6c77d
173 Nceeeb2c572a84b56bc29644caec6c77d rdf:first sg:person.01136565472.17
174 rdf:rest N480e69c445584d099763e8a14c6f037d
175 Nd133d4f886fd47a8afc33d02b7a99776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Immunoconjugates
177 rdf:type schema:DefinedTerm
178 Nd68c16360e7e4a929ce3d378f5001803 rdf:first sg:person.011754462047.20
179 rdf:rest N8eb34b91deab44e580c2867ee93d9db2
180 Nd75669ef0f70471bb2efc0253b2d99b2 rdf:first sg:person.01073066024.31
181 rdf:rest N00f74a988ff048f0b1c79b3b9689e78e
182 Ne22174745ec64eeb84684ba49d58a33d rdf:first sg:person.01221726245.27
183 rdf:rest N08e5cc8e020c4503b51c6a0e3aa75dca
184 Ne652aa385e6f4e36aa2e3464a762296c rdf:first sg:person.01050203042.17
185 rdf:rest N9d265bbb602945a6b61fa3c2c8ed5659
186 Ne7849ceb94494fd0825348e13d0d6103 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Antineoplastic Agents
188 rdf:type schema:DefinedTerm
189 Nea1ae026034e44d6baae0f469c4384c5 schema:issueNumber 5
190 rdf:type schema:PublicationIssue
191 Nf17f3c1c4244450983e757c39ff30391 rdf:first sg:person.07564140447.11
192 rdf:rest Nd75669ef0f70471bb2efc0253b2d99b2
193 Nf42aca013f994da690d8de72050f927e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Aged, 80 and over
195 rdf:type schema:DefinedTerm
196 Nfad33f36e05d4f12a1fee1fd03c51611 schema:name pubmed_id
197 schema:value 28527133
198 rdf:type schema:PropertyValue
199 Nfb1fc93be0264f9dbc428faff9cfdc17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Male
201 rdf:type schema:DefinedTerm
202 Nfc8a78e8ff384899b707e9f18ea6fc25 schema:volumeNumber 35
203 rdf:type schema:PublicationVolume
204 Nfe3f39e2e5bc4e19b7e5af7d49eafc53 rdf:first sg:person.01270750543.01
205 rdf:rest Nbbb039aae64043058496f717ca9800cb
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1094201 schema:issn 0167-6997
213 1573-0646
214 schema:name Investigational New Drugs
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01027130140.73 schema:affiliation grid-institutes:grid.468198.a
218 schema:familyName Almhanna
219 schema:givenName Khaldoun
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027130140.73
221 rdf:type schema:Person
222 sg:person.01050203042.17 schema:affiliation grid-institutes:grid.419849.9
223 schema:familyName Fasanmade
224 schema:givenName Adedigbo
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050203042.17
226 rdf:type schema:Person
227 sg:person.01053064323.39 schema:affiliation grid-institutes:grid.419849.9
228 schema:familyName Danaee
229 schema:givenName Hadi
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053064323.39
231 rdf:type schema:Person
232 sg:person.01073066024.31 schema:affiliation grid-institutes:grid.411347.4
233 schema:familyName Guillen-Ponce
234 schema:givenName Carmen
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073066024.31
236 rdf:type schema:Person
237 sg:person.01126575447.10 schema:affiliation grid-institutes:grid.412917.8
238 schema:familyName Hubner
239 schema:givenName Richard A.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126575447.10
241 rdf:type schema:Person
242 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.5072.0
243 schema:familyName Starling
244 schema:givenName Naureen
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
246 rdf:type schema:Person
247 sg:person.01162124377.34 schema:affiliation grid-institutes:grid.65499.37
248 schema:familyName Enzinger
249 schema:givenName Peter
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162124377.34
251 rdf:type schema:Person
252 sg:person.01174064377.38 schema:affiliation grid-institutes:grid.419513.b
253 schema:familyName Bendell
254 schema:givenName Johanna
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174064377.38
256 rdf:type schema:Person
257 sg:person.011754462047.20 schema:affiliation grid-institutes:grid.411062.0
258 schema:familyName Lopez
259 schema:givenName Carolina Muriel
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011754462047.20
261 rdf:type schema:Person
262 sg:person.01221726245.27 schema:affiliation grid-institutes:grid.430503.1
263 schema:familyName Messersmith
264 schema:givenName Wells
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221726245.27
266 rdf:type schema:Person
267 sg:person.01270750543.01 schema:affiliation grid-institutes:None
268 schema:familyName Bols
269 schema:givenName Alain
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270750543.01
271 rdf:type schema:Person
272 sg:person.01272603724.38 schema:affiliation grid-institutes:grid.81821.32
273 schema:familyName Feliu
274 schema:givenName Jaime
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272603724.38
276 rdf:type schema:Person
277 sg:person.013033516104.84 schema:affiliation grid-institutes:grid.419849.9
278 schema:familyName Kalebic
279 schema:givenName Thea
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013033516104.84
281 rdf:type schema:Person
282 sg:person.013532355330.01 schema:affiliation grid-institutes:grid.412157.4
283 schema:familyName Van Laethem
284 schema:givenName Jean-Luc
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013532355330.01
286 rdf:type schema:Person
287 sg:person.01365645263.42 schema:affiliation grid-institutes:grid.419849.9
288 schema:familyName Yang
289 schema:givenName Huyuan
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365645263.42
291 rdf:type schema:Person
292 sg:person.015007444517.20 schema:affiliation grid-institutes:grid.411083.f
293 schema:familyName Mercade
294 schema:givenName Teresa Macarulla
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007444517.20
296 rdf:type schema:Person
297 sg:person.016267211647.49 schema:affiliation grid-institutes:grid.428633.8
298 schema:familyName Wright
299 schema:givenName David
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267211647.49
301 rdf:type schema:Person
302 sg:person.016450520717.15 schema:affiliation grid-institutes:grid.267309.9
303 schema:familyName Mahalingham
304 schema:givenName Devalingham
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016450520717.15
306 rdf:type schema:Person
307 sg:person.0634644023.27 schema:affiliation grid-institutes:grid.32224.35
308 schema:familyName Faris
309 schema:givenName Jason
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634644023.27
311 rdf:type schema:Person
312 sg:person.07564140447.11 schema:affiliation grid-institutes:grid.8461.b
313 schema:familyName Gracian
314 schema:givenName Antonio Cubillo
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07564140447.11
316 rdf:type schema:Person
317 sg:pub.10.1007/s13238-016-0323-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034018913
318 https://doi.org/10.1007/s13238-016-0323-0
319 rdf:type schema:CreativeWork
320 sg:pub.10.1007/s13277-011-0231-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022738216
321 https://doi.org/10.1007/s13277-011-0231-0
322 rdf:type schema:CreativeWork
323 sg:pub.10.1023/a:1014231722696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012970787
324 https://doi.org/10.1023/a:1014231722696
325 rdf:type schema:CreativeWork
326 sg:pub.10.1038/bjc.2015.435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005211799
327 https://doi.org/10.1038/bjc.2015.435
328 rdf:type schema:CreativeWork
329 grid-institutes:None schema:alternateName Brugge Oostende Oncologisch Centrum, Bruges, Belgium
330 schema:name Brugge Oostende Oncologisch Centrum, Bruges, Belgium
331 rdf:type schema:Organization
332 grid-institutes:grid.267309.9 schema:alternateName University of Texas Health Science Center, San Antonio, TX, USA
333 schema:name University of Texas Health Science Center, San Antonio, TX, USA
334 rdf:type schema:Organization
335 grid-institutes:grid.32224.35 schema:alternateName Massachusetts General Hospital Cancer Center, Boston, MA, USA
336 schema:name Massachusetts General Hospital Cancer Center, Boston, MA, USA
337 rdf:type schema:Organization
338 grid-institutes:grid.411062.0 schema:alternateName Hospital Universitario Virgen de la Victoria, Málaga, Spain
339 schema:name Hospital Universitario Virgen de la Victoria, Málaga, Spain
340 rdf:type schema:Organization
341 grid-institutes:grid.411083.f schema:alternateName Vall d’Hebron University Hospital, Barcelona, Spain
342 schema:name Vall d’Hebron University Hospital, Barcelona, Spain
343 rdf:type schema:Organization
344 grid-institutes:grid.411347.4 schema:alternateName Ramón y Cajal University Hospital, Madrid, Spain
345 schema:name Ramón y Cajal University Hospital, Madrid, Spain
346 rdf:type schema:Organization
347 grid-institutes:grid.412157.4 schema:alternateName Erasme University Hospital, Brussels, Belgium
348 schema:name Erasme University Hospital, Brussels, Belgium
349 rdf:type schema:Organization
350 grid-institutes:grid.412917.8 schema:alternateName The Christie NHS Foundation Trust, Manchester, UK
351 schema:name The Christie NHS Foundation Trust, Manchester, UK
352 rdf:type schema:Organization
353 grid-institutes:grid.419513.b schema:alternateName Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
354 schema:name Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
355 rdf:type schema:Organization
356 grid-institutes:grid.419849.9 schema:alternateName Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
357 schema:name Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
358 rdf:type schema:Organization
359 grid-institutes:grid.428633.8 schema:alternateName Florida Cancer Specialists, Tampa, FL, USA
360 schema:name Florida Cancer Specialists, Tampa, FL, USA
361 rdf:type schema:Organization
362 grid-institutes:grid.430503.1 schema:alternateName University of Colorado, Aurora, CO, USA
363 schema:name University of Colorado, Aurora, CO, USA
364 rdf:type schema:Organization
365 grid-institutes:grid.468198.a schema:alternateName Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, 33612, Tampa, FL, USA
366 schema:name Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, 33612, Tampa, FL, USA
367 rdf:type schema:Organization
368 grid-institutes:grid.5072.0 schema:alternateName The Royal Marsden NHS Foundation Trust, London, UK
369 schema:name The Royal Marsden NHS Foundation Trust, London, UK
370 rdf:type schema:Organization
371 grid-institutes:grid.65499.37 schema:alternateName Dana Farber Cancer Institute, Boston, MA, USA
372 schema:name Dana Farber Cancer Institute, Boston, MA, USA
373 rdf:type schema:Organization
374 grid-institutes:grid.81821.32 schema:alternateName CIBERONC, La Paz University Hospital, Madrid, Spain
375 schema:name CIBERONC, La Paz University Hospital, Madrid, Spain
376 rdf:type schema:Organization
377 grid-institutes:grid.8461.b schema:alternateName Departamento de Ciencias Médicas Clínicas, Universidad San Pablo CEU, Madrid, Spain
378 schema:name Departamento de Ciencias Médicas Clínicas, Universidad San Pablo CEU, Madrid, Spain
379 HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain
380 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...